SCHEMBL2719397

SCHEMBL2719397

CC(N)c1cnc2ccccc2c1-c1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 4/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 3/20 0.41
HIF1A Q16665 2/20 0.41
POLB P06746 2/20 0.41
CYP1A2 P05177 1/20 0.41
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
BLM P54132 1/20 0.41
DOHH Q9BU89 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
TGFBR1 P36897 3/20 0.40
MAPK14 Q16539 2/20 0.40
TGFBR2 P37173 1/20 0.40
ABL2 P42684 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
MAP3K20 Q9NYL2 1/20 0.40
RAB9A P51151 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10200560 1.00 METAP1 (0.41) METAP1LMNAKDM4EHIF1APOLB
SCHEMBL2719485 0.86 METAP1 (0.41) METAP1LMNAKDM4EHIF1APOLB
SCHEMBL10200559 0.86 METAP1 (0.41) METAP1LMNAKDM4EHIF1APOLB
SCHEMBL2718686 0.83 PIK3CD (0.45) METAP1LMNAL3MBTL1
SCHEMBL2719827 0.82 ALDH1A1 (0.46) KDM4ECYP1A2KMT2AMEN1HTT
SCHEMBL2719771 0.79 PIK3CD (0.43) METAP1LMNAKDM4EHIF1APOLB
SCHEMBL2721133 0.77 ADORA2A (0.40) LMNAKDM4ECYP1A2MAPK14L3MBTL1
SCHEMBL4085689 0.75 PIK3CD (0.44)
SCHEMBL14122720 0.74 NCF1 (0.52) KDM4EHIF1ACYP1A2RAB9ANPC1
SCHEMBL13868218 0.74 NCF1 (0.52) KDM4EHIF1ACYP1A2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140031355-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2014-01-30 US disclosed
EP-2635565-A1 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS Amgen Inc. (US) 2013-09-11 EP disclosed
WO-2012061696-A1 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS AMGEN INC. (US) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031355-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, SSB, MALT1 METAP1 3316/4885LMNA 2393/4885KDM4E 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.